Scholars Central

Review articlePublished 2014

Non Biologic Complex Drug Concept: Experiences with Iron Sucrose and Low Molecular Weight Heparin

Authors: Jacques Rottembourg, Huub Schellekens

Journal of Blood & Lymph

Volume 4 · Issue 2 · Pages 1–5

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

When the patent of a small molecule drug expires, generics may be introduced. They are considered herapeutically equivalent once pharmaceutical equivalence (i.e. identical active substances) and bioequivalence i.e. comparable pharmacokinetics) have been established in cross-over volunteer study. However this generic paradigm cannot be applied to complex drugs as biologics. For copies of biologics EMA, and FDA, have introduced new regulatory bio-similar pathway which mandate clinical trials to show therapeutic equivalence. However for ome complex drugs, such as iron-carbohydrate drugs, low molecular weight heparins (named Non Biologic Complex Drugs [NBCD]), regulatory guidance is still mostly lacking. In this paper we will discuss therapeutic experiences with these different classes of complex drugs and their specificity, to provide scientific arguments for consideration for a new regulatory framework.

Subjects

Haematology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Blood & Lymph
  • SubjectHaematology
  • BylineArticles whose byline prints “Jacques Rottembourg”
  • BylineArticles whose byline prints “Huub Schellekens”